enGene Therapeutics Inc.
ENGN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001980845
In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 60 institutions reported holding it in 13F filings for Q2 2026, worth $86.5M in total; no superinvestor holds it.
Other share classesENGNW
13F holders, Q3 2025
Institutional positions in enGene Therapeutics Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 37
- +1 vs. Q2 2025
- Shares held
- 40.9M
- +448.0K (+1.1%) vs. Q2 2025
- Total value
- $279.1M
- +$132.0M (+89.7%) vs. Q2 2025
- New holders
- 7
- 7 more added
- Sold out
- 6
- 8 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENGN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 60 | $86.5M |
| Q1 2026 | 62 | $383.0M |
| Q4 2025 | 58 | $530.8M |
| Q3 2025 | 37 | $279.1M |
| Q2 2025 | 36 | $147.1M |
| Q1 2025 | 31 | $183.4M |
| Q4 2024 | 34 | $274.7M |
| Q3 2024 | 30 | $227.7M |
| Q2 2024 | 30 | $307.1M |
| Q1 2024 | 31 | $536.1M |
| Q4 2023 | 11 | $130.9M |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding enGene Therapeutics Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Citigroup Inc | 1 | $7 | 0.00% | +1 | New |
| SBI Securities Co., Ltd. | 31 | $212 | 0.00% | +1+3.3% | Added |
| MAI Capital Management | 776 | $5.30K | 0.00% | −2,149−73.5% | Reduced |
| Royal Bank of Canada | 7,915 | $54.0K | 0.00% | 00.0% | Unchanged |
| PFS Partners, LLC | 9,000 | $61.5K | 0.03% | +9,000 | New |
| Toronto Dominion Bank | 10,000 | $68.3K | 0.00% | −4,537−31.2% | Reduced |
| Raymond James Financial Inc | 10,000 | $68.3K | 0.00% | +7,932+383.6% | Added |
| Hudson Bay Capital Management LP | 11,074 | $75.6K | 0.00% | +11,074 | New |
| Pale Fire Capital SE | 17,254 | $117.8K | 0.01% | 00.0% | Unchanged |
| Wells Fargo & Company | 17,910 | $122.3K | 0.00% | +14,711+459.9% | Added |
| Millennium Management LLC | 20,502 | $140.0K | 0.00% | +7,472+57.3% | Added |
| Schonfeld Strategic Advisors LLC | 25,070 | $171.2K | 0.00% | −149,500−85.6% | Reduced |
| Geode Capital Management, LLC | 29,018 | $198.2K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 30,295 | $206.9K | 0.00% | −2,731−8.3% | Reduced |
| Citadel Advisors LLC | 58,370 | $398.7K | 0.00% | +35,327+153.3% | Added |
| Affinity Asset Advisors, LLC | 77,000 | $525.9K | 0.05% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 147,602 | $1.01M | 0.00% | −751,484−83.6% | Reduced |
| Marshall Wace, LLP | 343,928 | $2.35M | 0.00% | 00.0% | Unchanged |
| Vestal Point Capital, LP | 370,000 | $2.53M | 0.11% | 00.0% | Unchanged |
| Morgan Stanley | 435,291 | $2.97M | 0.00% | +82,523+23.4% | Added |
| Sphera Funds Management Ltd. | 504,409 | $3.45M | 0.82% | 00.0% | Unchanged |
| Omega Fund Management, LLC | 526,357 | $3.60M | 1.62% | 00.0% | Unchanged |
| MPM Oncology Impact Management LP | 530,299 | $3.62M | 0.59% | +530,299 | New |
| Bank of America Corp | 647,192 | $4.42M | 0.00% | −1,358,516−67.7% | Reduced |
| Sr One Capital Management, LP | 747,750 | $5.11M | 0.74% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 1,000,000 | $6.83M | 0.01% | 00.0% | Unchanged |
| Franklin Resources Inc | 1,038,000 | $7.09M | 0.00% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 1,157,380 | $7.90M | 0.24% | +1,157,380 | New |
| Point72 Asset Management, L.P. | 1,208,399 | $8.25M | 0.02% | +1000.0% | Added |
| Perceptive Advisors LLC | 2,097,236 | $14.3M | 0.41% | +2,097,236 | New |
| Deep Track Capital, LP | 2,239,353 | $15.3M | 0.43% | −2,318,222−50.9% | Reduced |
| Braidwell LP | 2,266,319 | $15.5M | 0.46% | +2,266,319 | New |
| Cormorant Asset Management, LP | 2,323,595 | $15.9M | 1.10% | 00.0% | Unchanged |
| Blue Owl Capital Holdings LP | 3,278,106 | $22.4M | 6.95% | −450,000−12.1% | Reduced |
| Kynam Capital Management, LP | 4,994,090 | $34.1M | 2.54% | 00.0% | Unchanged |
| VR Adviser, LLC | 5,046,414 | $34.5M | 1.94% | 00.0% | Unchanged |
| FCPM III Services B.V. | 9,632,561 | $65.8M | 13.15% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 0 | $0 | 0.00% | −677,977−100.0% | Sold out |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −27,787−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −11,400−100.0% | Sold out |
| Paloma Partners Management Co | 0 | $0 | 0.00% | −10,319−100.0% | Sold out |
| Wolverine Asset Management LLC | 0 | $0 | 0.00% | −6,361−100.0% | Sold out |
| NBC Securities, Inc. | 0 | $0 | 0.00% | −380−100.0% | Sold out |